Skip to content
The Peptide TablePeptide Table
Subscribe
Weight-loss drugs in trials

Retatrutide: Real Trials, Unknown Vials

Lilly's retatrutide trials in one table, kept apart from the vials sold under its name.

  1. 1The FDA and the EMA have not approved retatrutide; Eli Lilly plans to apply to the FDA in early 2027.1,2
  2. 2The largest published trial: people given the most drug lost 25.0% of their weight on average, against 3.9% on placebo.3
  3. 3Vials sold under its name were never in those trials; a counterfeit tested by Australia's regulator held semaglutide, no retatrutide.4,2
Read the short answer

The short answer

Retatrutide is an experimental drug from Eli Lilly.1 It is one molecule that acts on three hormone receptors: GIP, GLP-1 and glucagon.5 Online it is nicknamed "GLP-3".6 Lilly's trials are large, and most are in medical journals.7,8,9,3,10 The FDA and the EMA have not approved it.1,2 Lilly says it "cannot be legally sold or marketed for human use."1 The vials sold under its name were never in those trials.4

Same name, two different things1,2
Made by
Lilly's retatrutide
Eli Lilly
Vials sold as retatrutide
Unknown
Tested in people
Lilly's retatrutide
7 trials, over 7,000 people
Vials sold as retatrutide
Never in those trials
FDA or EMA approval
Lilly's retatrutide
No; FDA filing planned, early 2027
Vials sold as retatrutide
No
Contents
Lilly's retatrutide
Retatrutide
Vials sold as retatrutide
One tested: semaglutide, no retatrutide

7 trials: the Phase 2 and Phase 3 trials with results that we found, over 7,000 people in all.7,8,5,9,3,11,10 The tested vial: Australia's regulator, the TGA, 14 Sep 2026.2

18.8%

average weight lost over 80 weeks by TRIUMPH-2's top group, the people given the most drug. It counts everyone who started. The trial's 1,152 adults had type 2 diabetes and excess weight.10

5.1% on placebo, a dummy shot

The catch
Every trial result here comes from Lilly's own drug, in amounts Lilly chose, with doctors watching. None of it tells you what is in a vial bought online.

The full PDF, free.

  • Seven trials with results in one table: people, weeks, main result, and whether a journal published it or Lilly only announced it.
  • A dated timeline from the first trial in people, in 2019, to the FDA filing Lilly plans for early 2027.
  • The side effects the trials counted, and how many people stopped because of them.
  • Australia's lab test and Victoria's liver-injury alert on products sold as retatrutide, in their own words.

A source on every line. No paid placements. No doses.

Instant download. You also get the Wednesday email, which you can leave on the first click. Privacy

The fair line
The trial numbers describe Lilly's own drug, in amounts Lilly chose, with doctors watching, not a vial bought online. Every trial here is Lilly's own, and two are known only from its press releases.4,3,9,10

This guide was last checked on 28 October 2026. Research and educational information only. Nothing here is medical advice.

  1. [1] Eli Lilly news release, 29 Sep 2026: TRIUMPH-2 results and the FDA filing plan (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 1)
  2. [2] Therapeutic Goods Administration (Australia), safety advisory, 14 Sep 2026 (opens in new tab). Checked 14 Sep 2026Back to text (first mention of source 2)
  3. [3] Jastreboff et al., TRIUMPH-1, NEJM, 29 Sep 2026 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 3)
  4. [4] Eli Lilly news release, 21 May 2026: TRIUMPH-1 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 4)
  5. [5] Eli Lilly news release, 11 Dec 2025: TRIUMPH-4 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 5)
  6. [6] Google search suggestions for "glp-3" (United States, English), 28 Oct 2026 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 6)
  7. [7] Jastreboff et al., Phase 2 obesity trial, NEJM, 26 Jun 2023 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 7)
  8. [8] Rosenstock et al., Phase 2 type 2 diabetes trial, The Lancet, 26 Jun 2023 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 8)
  9. [9] Bajaj et al., TRANSCEND-T2D-1, The Lancet, 6 Jun 2026 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 9)
  10. [10] Bellido et al., TRIUMPH-2, The Lancet, 29 Sep 2026 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 10)
  11. [11] Eli Lilly news release, 23 Jul 2026: TRIUMPH-2 and TRIUMPH-3 (opens in new tab). Checked 28 Oct 2026Back to text (first mention of source 11)
  12. [12] ClinicalTrials.gov, NCT03841630: Lilly's first trial in people (2019) (opens in new tab). Checked 28 Oct 2026
  13. [13] Victorian Department of Health (Australia), health alert, 19 Jun 2026 (opens in new tab). Checked 28 Oct 2026
  14. [14] WADA, The 2026 Prohibited List (in force from 1 Jan 2026), section S0 (opens in new tab). Checked 28 Oct 2026
  15. [15] Ozempic label (Novo Nordisk, revised 5/2026), section 11 (opens in new tab). Checked 28 Oct 2026
  16. [16] Mounjaro label (Eli Lilly, revised 8/2026), section 12.1 (opens in new tab). Checked 28 Oct 2026
  17. [17] Merriam-Webster Medical Dictionary: dysesthesia (opens in new tab). Checked 28 Oct 2026

More free guides